John Pace

Biography

 John Pace, Ph.D. is an Executive Director at ATCC Center of Translational Microbiology and Vice President at AntibioTx. Dr. Pace has more than 20 years of biopharma experience from leading pharmaceutical companies and contributed to the discovery and advancement of 12 clinical candidates including four anti-infectives which are now marketed. Dr. Pace is the co-inventor of Vibativ® which has been globally approved for complicated skin MRSA infections and Hospital-Acquired Bacterial Pneumonia, as well as three anti-infective clinical candidates. Dr. Pace was a Director of Clinical Development at GSK Stiefel and has rich experience in topical antibiotics with a particular focus on Retapamulin for treatment of skin infections. As a Director of Anti-Infective Pharmacology, he led the in-vitro and in-vivo antibacterial discovery and support of clinical development in Novexel leading to a successful deal with Forest Laboratories and subsequently by AstraZeneca. John completed his B.Sc. at Salisbury University and M.Sc. in Food Science from University of Maryland College Park. He received his Ph.D. in Food Sciences from University of Maryland College Park.

Research Interest

 Toxicology